In October 2023, NICE (the National Institute for Health and Care Excellence) approved Mounjaro (tirzepatide) for use on the NHS in England for adults with obesity. The rollout began in 2024 through specialist weight management services, with broader GP access expected to follow. However, the reality for most patients has been long waiting lists and limited availability.
NICE guidance specifies that NHS Mounjaro is available to adults who meet all of the following criteria:
- BMI of 35 or above (or 32.5+ for certain ethnic groups with higher health risk)
- At least one weight-related comorbidity (e.g. type 2 diabetes, hypertension, sleep apnoea)
- Referred to a specialist NHS weight management service (Tier 3 or above)
- Have not responded adequately to lifestyle interventions alone
NHS Mounjaro is currently only available through specialist weight management services in England. It is not yet available through standard GP prescriptions in most areas.
Waiting times for NHS specialist weight management services vary significantly by region. In some areas, patients report waiting 12–24 months for a Tier 3 appointment. In others, services have been paused due to funding pressures. The NHS Long Term Plan aims to expand access, but progress has been slow.
For patients who meet the NHS criteria but face long waiting lists, private prescription remains the fastest route to treatment. With prices now starting from around £139/month for the 2.5mg dose — and many pharmacies offering discount codes for first orders — the cost of private treatment has become more accessible than it was at launch.
| Factor | NHS Mounjaro | Private Mounjaro |
|---|---|---|
| Cost | Free (prescription charge applies) | From ~£139/month |
| Waiting time | 12–24 months in many areas | As fast as 24–48 hours |
| Eligibility | BMI 35+ with comorbidity | BMI 27+ (varies by pharmacy) |
| Support | Specialist MDT support | Varies by pharmacy |
| Availability | England only (limited) | UK-wide |
NHS Mounjaro availability differs across the devolved nations. Scotland's SMC (Scottish Medicines Consortium) approved tirzepatide in 2024, but rollout through NHS Scotland is at an earlier stage. Wales and Northern Ireland are following their own approval timelines. Private prescription is available UK-wide regardless of NHS availability.